cea gene modified t cells
Cell therapyexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00664196)
Timeline
Indications
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cea gene modified t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01723306 | Phase 2 | Oct 1, 2012 | Boston University |
| NCT00673322 | Phase 1 | May 1, 2008 | Boston University |
| NCT00673829 | Phase 1 | May 1, 2008 | Boston University |
| NCT00664196 | Phase 1 | Apr 1, 2008 | Boston University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston University | Academic/Hospital | 4 | 4 | 2 | 2008 |
1 organizations
Page 1 / 1